A New Valuation: How Regulatory Is Becoming An Increasingly Valuable Asset

By Hal Stowe, Eurofins Medical Device Services

The companies that will define the next decade of medical device innovation are being chosen now — and the key filter isn’t technology, but regulatory sophistication. The era when innovation and clinical impact alone drove investment decisions is over. Today, medtech is shaped by risk: anticipating it, minimizing it, and integrating it strategically from the earliest stages, as more responsibility shifts to sponsors.

In a tight capital environment, and with an FDA that increasingly signals policy publicly rather than through industry collaboration, regulatory strategy has moved from a support role to a core value driver. This shift is clear to experienced founders and investors who have seen how regulatory missteps affect outcomes. Regulatory strategy is no longer just about navigating submissions or responding to FDA feedback. Companies must now be built for commercial launch — not as IP incubators for acquisition. Regulatory should function less like a soloist and more like a conductor, aligning data, policy, and market insight into a cohesive strategy.

This piece will go beyond basic frameworks or 510(k) overviews. It will examine the current regulatory and capital landscape — both micro and macro — and explore the strategic implications for sponsors and investors.